A Phase 1 Study of Anitocabtagene Autoleucel for the Treatment of Subjects With Non-oncology Plasma Cell-related Diseases

Study Summary

A Phase 1 dose-escalation study designed to evaluate the safety, tolerability, and preliminary efficacy of anito-cel in subjects with generalized myasthenia gravis (GMG). Anitocabtagene autoleucel (anito-cel) is a BCMA-directed CAR-T cell therapy.

Conditions

Muscular Diseases Neuromuscular Manifestations Autoimmune Autoimmune Diseases Autoimmune Diseases of the Nervous System Myasthenia Gravis Muscle Weakness

Interventions / Drugs

anito-cel Standard Lymphodepletion regimen

View on ClinicalTrials.gov ↗

Sponsor

Study Details

Enrollment30 participants

Primary Completion—

Lead SponsorArcellx, Inc.

Data Retrieved2026-04-11 02:52:14.610042+00:00

Not financial advice. BiotechSigns data is sourced from ClinicalTrials.gov, SEC EDGAR, and other public databases for research and informational purposes only. It does not constitute investment recommendations. Always do your own due diligence before making investment decisions.